Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887532 | 0.84 | TAS2R14 (0.57) | AKR1B1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL6885996 | 0.84 | AKR1B1 (0.57) | AKR1B1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL17319547 | 0.82 | TAS2R14 (0.81) | AKR1B1MEN1MAPTKMT2ATAS2R14 | |
| SCHEMBL6884847 | 0.81 | TAS2R14 (0.60) | AKR1B1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL6881090 | 0.79 | KMT2A (0.65) | AKR1B1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL6885986 | 0.79 | AKR1B1 (0.64) | AKR1B1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL13005078 | 0.78 | TAS2R14 (0.80) | AKR1B1MEN1KMT2ATAS2R14PDE4B | |
| SCHEMBL12008785 | 0.78 | TAS2R14 (0.85) | MEN1MAPTKMT2AALDH1A1TAS2R14 | |
| SCHEMBL18095845 | 0.78 | MEN1 (0.74) | AKR1B1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL20558646 | 0.78 | AKR1B1 (0.60) | AKR1B1MEN1KMT2ATAS2R14PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673816-B1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | Esswein, Angelika (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD | 2003-02-13 | — | — | US | disclosed |
| EP-1117655-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | Esswein, Angelika (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018747-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | NR1H4, NR1D1, NR1I2 | AKR1B1 417/4885MEN1 838/4885MAPT 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.